12:00 AM
 | 
Dec 14, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Taliglucerase alfa regulatory update

Protalix completed submission of a rolling NDA to FDA for taliglucerase alfa to treat Gaucher's disease. The company also announced that it submitted its proposed pediatric...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >